An issue of Endo International PLC (NASDAQ:ENDP) bonds rose 1.2% as a percentage of their face value during trading on Tuesday. The high-yield issue of debt has a 7.75% coupon and is set to mature on January 15, 2022. The bonds in the issue are now trading at $99.19. Price changes in a company’s bonds in credit markets often anticipate parallel changes in its share price.
Several equities analysts have commented on ENDP shares. Vetr raised shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 target price on the stock in a research report on Tuesday, May 9th. Mizuho reaffirmed a “buy” rating and issued a $18.00 price target (up from $17.00) on shares of Endo International PLC in a research report on Thursday, April 13th. Deutsche Bank AG lowered their price target on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th. BMO Capital Markets reaffirmed a “hold” rating and issued a $16.00 price target on shares of Endo International PLC in a research report on Wednesday, May 17th. Finally, Canaccord Genuity set a $14.00 price target on Endo International PLC and gave the company a “hold” rating in a research report on Thursday, May 11th. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have issued a buy rating to the company’s stock. Endo International PLC currently has a consensus rating of “Hold” and an average target price of $17.18.
Shares of Endo International PLC (ENDP) traded down 12.14% on Tuesday, reaching $8.18. 22,095,179 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $11.36 and its 200 day moving average price is $11.72. Endo International PLC has a 12 month low of $8.15 and a 12 month high of $24.93. The company’s market cap is $1.83 billion.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same quarter in the prior year, the business posted $0.86 EPS. The business’s revenue was down 4.9% compared to the same quarter last year. Equities research analysts predict that Endo International PLC will post $3.53 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Macquarie Group Ltd. raised its position in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the last quarter. Americafirst Capital Management LLC purchased a new stake in shares of Endo International PLC during the first quarter worth $286,000. Hartford Investment Management Co. purchased a new stake in shares of Endo International PLC during the first quarter worth $1,363,000. Nationwide Fund Advisors increased its stake in shares of Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares during the period. Finally, First Quadrant L P CA purchased a new stake in shares of Endo International PLC during the first quarter worth $24,556,000. Hedge funds and other institutional investors own 93.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/endo-international-plc-endp-bonds-rise-1-2-during-trading/1409335.html.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with our FREE daily email newsletter.